A notable example of TCIs is Ibrutinib (Figure 1A), a first-in-class BTK inhibitor approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia (CLL). Here, BTK is linked to B-cell chronic lymphocytic leukemia.